N | Median Age (Range) | Regimen | Histologies | R (%) | HIV (%) | ORR (%) | CR (%) | 2 Year EFS (%) | 2 Year OS (%) | TRM (%) | Completed Therapy (%) | |
Magrath [3] (1996) | 41 | Child = 12; Adult = 25 (3 - 59) | Protocol 89-C-41 (CODOX-M IVAC) | SNCL | 0 | 0 | 100 | 95 | 92 | 95h | 0 | 93 |
Mead [7] (2002) | 52 | 35 (16 - 60) | Modified 89-C-41a | BL only, defined by morphology and Ki-67 of 100% | 0 | 0 | 87 | 77 | 65 | 73 | 12 | 79 |
Lacasce [6] (2004) | 14 | 47 (18 - 65) | Modified 89-C-41b | BL and BCL-U, defined by morphology and Ki-67 > 90% | 0 | 0 | 86 | 86 | 64f | 71 | 0 | 100 |
Mead [5] (2008) | 110 | 37 (17 - 76) | Modified 89-C-41c | Aggressive B cell lymphoma with Ki67 fraction approaching 100%i | 0 | 0 | N/A | N/A | 64f | 67 | 17 | 72 |
Maruyama [9] (2010) | 15 | 39 (19 - 59) | Modified 89-C-41d R day 1 each cycle | 4BL and 11 intermediate DLBCL/BL | 60 | 0 | 87 | 87 | 87 | 87 | 0 | 80 |
Barnes [18] (2011) | 80 | 46 (17 - 78) | Modified 89-C-41b R day 1 each cycle | BL, defined by REAL or WHO criteria at diagnosis | 50 | 18 | 89 | 88 | 68g | 71g | 6 | 87 |
Mohamedbhai [10] (2011) | 23 | NR (19 - 65) | 89-C-41 R days 1, 10 each cycle | BCNHL with proliferation index > 95% | 100 | 0 | 87 | 61 | N/A | 83h | 0 | 91 |
Corazzelli [11] (2012) | 30 | 52 (25 - 77) | Modified 89-C-41 R days 1 of each cyclee | BL and BCL-U, defined by morphology | 100 | 0 | 93 | 93 | 78j | 82j | 0 | 80 |
Wasterlid [17] (2013) | 32 | 42 | Modified 89-C-41a R days 1 of each cyclee | BL only, defined by morphology and Ki-67 of >95% | 44 | 0 | NR | NR | NR | 69 | NR | NR |
Present study | 31 | 45 (20 - 74) | Modified 89-C-41a | BL and BCL-U, defined by morphology | 71 | 0 | 68 | 65 | 62f | 69 | 16 | 71 |